pharma · Clear Cell Renal Cell Carcinoma · Cushing s Syndrome
Peking University Biologics
Peking University Third Hospital
Peking University Third is a pharma organization headquartered in CN. Primary therapeutic focus areas include Clear Cell Renal Cell Carcinoma, Cushing s Syndrome, Esophageal Cancer, Prostate Cancer, Aged. NovaPharmaNews
仙霞路, 319号, 上海市, 长宁区, CN HQ
2018 Founded
8 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 仙霞路, 319号, 上海市, 长宁区, CN
- Founded
- 2018
- Employees
- 8
- Programs
- 15
- Drugs
- 25
- Patents
- 0
68Ga-Pentixafor
Phase 2 · small molecule · Cushing s Syndrome
68Ga-Pentixafor for Cushing s Syndrome is a Phase 2 program (small_molecule) at Peking University Third Hospital with 1 ClinicalTrials.gov record(s).
Internal code PUMCH-68Ga-CXCR4-Cushing
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Peking University Third Hospital
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Cushing s Syndrome
- Status
- active
- Trials
- 1